NOVO NORDISK'S RETATRUTIDE: THE NEW HOPE FOR BODY CONTROL?

New clinical data suggests that Novera Retatrutide, a twin-action therapy from Novo Nordisk, could offer a substantial breakthrough in weight control. Beyond many existing drugs, Retatrutide targets both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), potentially producing to greate